KURA
BEARISH
$8.67
Live
Kura Oncology, Inc. · NASDAQ
Target $31.82
(+267.0%)
$5.45
52W Range
$12.49
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$765.82M
P/E
N/A
ROE
-94.8%
Profit margin
N/A
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
KURA presents a contradictory profile with a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 6.06), yet suffers from severe fundamental decay. The company has experienced a catastrophic revenue decline of -67.80% YoY and has missed earnings estimates in four consecutive quarters with an average surprise of -50.91%. While the analyst target price of $31.82 suggests significant upside, this is decoupled from the current financial reality of negative gross margins (-272.14%) and bearish insider activity. The stock is currently a speculative play on pipeline success rather than a value or growth investment based on existing data.
Key Strengths
Strong liquidity position with a Current Ratio of 6.06
Very low leverage with a Debt/Equity ratio of 0.12
Stable Piotroski F-Score (6/9) indicating baseline operational stability
Significant positive gap between current price ($8.67) and analyst target ($31.82)
Strong 1-year price recovery (+54%)
Key Risks
Severe revenue contraction (-67.80% YoY and Q/Q)
Consistent earnings misses (0/4 beats in the last year)
Deeply negative profitability (Operating Margin -497.62%)
Bearish insider sentiment with 11 sell transactions and 0 buys
Negative technical trend (0/100 score)
AI Fair Value Estimate
Based on comprehensive analysis
$11.5
+32.6% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
33
Weak
25
20
45
75
0
AI Verdict
Speculative/High Risk
Key drivers: Revenue collapse, Strong balance sheet liquidity, Insider divestment, Earnings volatility
Confidence
90%
Value
25/100
P/E is N/A; Graham Number cannot be calculated due to lack of earnings.
Positives
- Low debt
Watchpoints
- High Price/Sales (11.35) relative to shrinking revenue
- Price/Book of 4.37 is high for a non-profitable entity
Future
20/100
Growth metrics are currently in a state of collapse.
Positives
- High analyst price targets
Watchpoints
- Revenue growth is deeply negative (-67.8%)
- Earnings trajectory is worsening
Past
45/100
Historical trend shows long-term value destruction despite short-term bounces.
Positives
- 1Y price return of +54%
Watchpoints
- 5Y change of -69.7%
- Consistent failure to meet EPS estimates recently
Health
75/100
Health is the only strong pillar, driven by cash reserves rather than operational efficiency.
Positives
- Piotroski F-Score 6/9
- Current Ratio 6.06
- Quick Ratio 5.81
Watchpoints
- Negative ROE (-94.82%)
Dividend
0/100
Typical for early-stage biotech.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$8.67
Analyst Target
$31.82
Upside/Downside
+267.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KURA and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KURA
Kura Oncology, Inc.
Primary
|
-69.7% | -27.5% | +54.0% | -12.0% | -6.0% | +0.7% |
|
IART
Integra LifeSciences Holdings Corporation
Peer
|
-85.7% | -83.0% | -43.2% | -25.8% | +3.0% | +3.9% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
|
BGM
BGM Group Ltd.
Peer
|
-90.8% | -38.2% | -66.0% | -64.4% | -12.5% | 0.0% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
KUR
Kura Oncology, Inc.
Primary
5Y
-69.7%
3Y
-27.5%
1Y
+54.0%
6M
-12.0%
1M
-6.0%
1W
+0.7%
IAR
Integra LifeSciences Holdings Corporation
Peer
5Y
-85.7%
3Y
-83.0%
1Y
-43.2%
6M
-25.8%
1M
+3.0%
1W
+3.9%
ARV
Arvinas, Inc.
Peer
5Y
-84.3%
3Y
-57.8%
1Y
+42.5%
6M
+57.4%
1M
-7.0%
1W
-10.4%
BGM
BGM Group Ltd.
Peer
5Y
-90.8%
3Y
-38.2%
1Y
-66.0%
6M
-64.4%
1M
-12.5%
1W
0.0%
AMN
AMN Healthcare Services, Inc.
Peer
5Y
-72.8%
3Y
-78.8%
1Y
-26.3%
6M
+3.5%
1M
+28.0%
1W
+7.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-3.55
PEG Ratio
N/A
P/B Ratio
4.37
P/S Ratio
11.35
EV/Revenue
1.76
EV/EBITDA
-0.39
Market Cap
$765.82M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-497.62%
Gross Margin
-272.14%
ROE
-94.82%
ROA
-25.33%
Growth
Revenue and earnings growth rates
Revenue Growth
-67.8%
Earnings Growth
N/A
Q/Q Revenue Growth
-67.83%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
6.06
Strong
Quick Ratio
5.81
Excellent
Cash/Share
$7.55
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-497.6%
Net Margin
-467.2%
Total Assets
$0.7B
Liabilities
$0.6B
Equity
$0.2B
Debt/Equity
3.24x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
98%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-03-05
$-0.92
-24.1% surprise
2025-11-04
$-0.85
-25.8% surprise
2025-08-07
$-0.75
-102.8% surprise
Healthcare Sector Comparison
Comparing KURA against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-94.82%
This Stock
vs
-49.88%
Sector Avg
+90.1%
(Excellent)
Debt to Equity
0.12
This Stock
vs
3.74
Sector Avg
-96.9%
(Less Debt)
Revenue Growth
-67.8%
This Stock
vs
80.78%
Sector Avg
-183.9%
(Slower)
Current Ratio
6.06
This Stock
vs
3.72
Sector Avg
+62.9%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KURA
Kura Oncology, Inc.
|
BEARISH | $765.82M | - | -94.8% | -% | $8.67 | |
|
IART
Integra LifeSciences...
|
NEUTRAL | $771.58M | - | -39.9% | -31.6% | $9.9 | Compare |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | Compare |
|
BGM
BGM Group Ltd.
|
BEARISH | $746.32M | - | -16.5% | -26.3% | $3.72 | Compare |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 | Compare |
KURA
Kura Oncology, Inc.
BEARISH
Mkt Cap
$766M
P/E
-
ROE
-94.8%
Price
$8.67
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | WILSON TROY EDWARD | Chief Executive Officer | Option Exercise | 6,103 | $37,533 |
| 2026-03-18 | MALLEY THOMAS ROBERT | Director | Option Exercise | 10,000 | $31,200 |
| 2026-01-27 | FORD KATHLEEN | Chief Operating Officer | Sale | 1,813 | $15,339 |
| 2026-01-27 | BAIR TERESA BROPHY | Officer | Sale | 11,208 | $94,828 |
| 2026-01-27 | DOYLE THOMAS JAMES | Officer | Sale | 7,142 | $60,426 |
| 2026-01-27 | POWL BRIAN T | Officer | Sale | 6,414 | $54,266 |
| 2026-01-27 | LEONI MOLLIE M.D. | Officer | Sale | 8,180 | $69,209 |
| 2026-01-27 | BURROWS FRANCIS J. PH.D. | Officer | Sale | 1,311 | $11,092 |
| 2026-01-02 | FORD KATHLEEN | Chief Operating Officer | Stock Award | 50,000 | - |
| 2026-01-02 | BAIR TERESA BROPHY | Officer | Stock Award | 50,000 | - |
| 2026-01-02 | DOYLE THOMAS JAMES | Officer | Stock Award | 21,250 | - |
| 2026-01-02 | POWL BRIAN T | Officer | Stock Award | 50,000 | - |
| 2026-01-02 | LEONI MOLLIE M.D. | Officer | Stock Award | 50,000 | - |
| 2025-12-18 | BURROWS FRANCIS J. PH.D. | Officer | Sale | 23,726 | $231,931 |
| 2025-12-18 | BURROWS FRANCIS J. PH.D. | Officer | Option Exercise | 35,000 | $168,000 |
WILSON TROY EDWARD
Chief Executive Officer
2026-03-23
6,103 shares
·
$37,533
MALLEY THOMAS ROBERT
Director
2026-03-18
10,000 shares
·
$31,200
FORD KATHLEEN
Chief Operating Officer
2026-01-27
1,813 shares
·
$15,339
BAIR TERESA BROPHY
Officer
2026-01-27
11,208 shares
·
$94,828
DOYLE THOMAS JAMES
Officer
2026-01-27
7,142 shares
·
$60,426
POWL BRIAN T
Officer
2026-01-27
6,414 shares
·
$54,266
LEONI MOLLIE M.D.
Officer
2026-01-27
8,180 shares
·
$69,209
BURROWS FRANCIS J. PH.D.
Officer
2026-01-27
1,311 shares
·
$11,092
FORD KATHLEEN
Chief Operating Officer
2026-01-02
50,000 shares
BAIR TERESA BROPHY
Officer
2026-01-02
50,000 shares
DOYLE THOMAS JAMES
Officer
2026-01-02
21,250 shares
POWL BRIAN T
Officer
2026-01-02
50,000 shares
LEONI MOLLIE M.D.
Officer
2026-01-02
50,000 shares
BURROWS FRANCIS J. PH.D.
Officer
2025-12-18
23,726 shares
·
$231,931
BURROWS FRANCIS J. PH.D.
Officer
2025-12-18
35,000 shares
·
$168,000
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
11 analysts
Mizuho
2026-03-24
Outperform
Outperform
UBS
2026-03-13
Buy
Buy
Wedbush
2026-03-06
Outperform
Outperform
Leerink Partners
2026-01-13
Outperform
Outperform
HC Wainwright & Co.
2026-01-13
Buy
Buy
Barclays
2025-11-24
Overweight
Overweight
UBS
2025-11-14
Buy
Buy
Wedbush
2025-11-14
Outperform
Outperform
JMP Securities
2025-10-20
Market Outperform
Market Outperform
HC Wainwright & Co.
2025-10-20
Buy
Buy
Past News Coverage
Recent headlines mentioning KURA from our newsroom.
Newest → oldest
No matching news yet.